Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program

Documenti analoghi

• Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant focal epilepsies treated in the Expanded Access Program
  di: Anup D. Patel, et al.
  Pubblicazione: (2025)
• Accumulated seizure burden predicts neurodevelopmental outcome at 36 months of age in patients with tuberous sclerosis complex
  di: S. Katie Z. Ihnen, et al.
  Pubblicazione: (2024)
• Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis
  di: Renzo Guerrini, et al.
  Pubblicazione: (2024)
• Successful use of cannabidiol in nonconvulsive status epilepticus in Angelman syndrome
  di: Nicola Pietrafusa, et al.
  Pubblicazione: (2024)
• Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy
  di: Cecilie Johannessen Landmark, et al.
  Pubblicazione: (2025)